Date: 2016-06-02
Type of information: Nomination
Compound:
Company: Arsanis (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
Financial terms:
Latest news: * On June 2, 2016, Arsanis announced it has appointed Anthony Christopher (Chris) Stevens, MD, as chief medical
officer. In this role, Dr. Stevens will drive the clinical development strategy for the full pipeline, including lead candidate ASN100 for the prevention and treatment of serious Staphylococcus aureus infections. Dr. Stevens joins Arsanis with more than 17 years of senior management and consulting experience in drug development, including strategy, execution and operations management for U.S. and European clinical trials and regulatory filings. Prior to joining Arsanis, Dr. Stevens spent more than a decade consulting for nearly 30 companies assisting with all stages of drug development in the United States and Europe. While working with Cubist, he guided the development strategy for surotomycin for the treatment of C. difficile infection from IND filing to the completion of its successful phase 2 trial. As a strategic consultant for Dyax, he supported the development of peptide and monoclonal antibody therapies for hereditary angioedema. He also served on the Millenium/Takeda team that led to the approval of vedolizumab for both Crohn’s disease and ulcerative colitis treatment indications in the United States and Europe. He served as senior vice president of clinical development at Alnara Pharmaceuticals, and also previously held medical director roles at Circe Biomedical and Altus Pharmaceuticals. Dr. Stevens spent 10 years as a clinical and research gastroenterologist at Beth Israel Deaconess Medical Center in Boston and as an assistant professor of medicine at Harvard Medical School, during which he authored more than 30 peer-reviewed publications.
In addition to planning for the initiation of phase 2 clinical studies with ASN100 for S. aureus pneumonia in the second half of 2016, Arsanis also continues to advance earlier-stage mAb candidates targeting specific mechanisms of serious Gram-negative and Gram-positive infections, including Escherichia coli, Klebsiella pneumonia and Streptococcus pneumoniae.
